Clinical trials
Suspended trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
154 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2013 | 6 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 3 |
| 2018 | 8 |
| 2019 | 14 |
| 2020 | 12 |
| 2021 | 11 |
| 2022 | 16 |
| 2023 | 11 |
| 2024 | 17 |
| 2025 | 19 |
| 2026 | 11 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Suspended | 154 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sclnow Biotechnology Co., Ltd. | 8 |
| Sun Yat-sen University | 5 |
| Wondercel Biotech (ShenZhen) | 5 |
| Bioray Laboratories | 4 |
| Peking Union Medical College Hospital | 4 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 3 |
| Guangzhou Women and Children's Medical Center | 3 |
| Innovent Biologics (Suzhou) Co. Ltd. | 3 |
| Jiangsu HengRui Medicine Co., Ltd. | 3 |
| Peking University People's Hospital | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colorectal Neoplasms | 7 |
| Carcinoma, Hepatocellular | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Breast Neoplasms | 4 |
| COVID-19 | 4 |
| Hypertension | 4 |
| Multiple Myeloma | 4 |
| Carcinoma, Renal Cell | 3 |
| Heart Failure | 3 |
| Hypoparathyroidism | 3 |
Trials
Showing 1 to 25 of 154. Each trial links to its page on Pharma Observatory.
54 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.